Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of POS (0.75% Phentolamine Ophthalmic Solution) in Subjects Who Have Previously Had Keratorefractive Surgery and Have Decreased Visual Acuity Under Mesopic Conditions

Next Previous
Trial Profile

Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of POS (0.75% Phentolamine Ophthalmic Solution) in Subjects Who Have Previously Had Keratorefractive Surgery and Have Decreased Visual Acuity Under Mesopic Conditions

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Phentolamine (Primary)
  • Indications Nyctalopia
  • Focus Registrational; Therapeutic Use
  • Acronyms LYNX-2
  • Sponsors Ocuphire Pharma

Most Recent Events

  • 02 Jun 2025 Results presented in the Viatris Inc Media Release.
  • 02 Jun 2025 According to an Opus Genetics media release, the study was conducted under FDA Fast-Track Designation.
  • 02 Jun 2025 Primary endpoint has been met. (Percent of subjects with an increase of at least 15 ETDRS letters read ( 3 lines) in the study eye in mLCVA compared to), according to an Opus Genetics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top